Aquaculture Medicine Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Aquaculture medicine sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹4.7 crore - ₹52 crore CapEx this DPR captures:

• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The India aquaculture inputs and supplements market reached INR 42.2 billion in 2025 and is projected to scale up to INR 104.4 billion by 2034, registering a compound annual growth rate of 10.27 percent (IMARC Group). The broader Indian aquaculture market generated USD 21,866.2 million in revenue in 2024 and is expected to grow at a 5.5 percent CAGR through 2030, reaching USD 30.14 billion by 2030. On the feed side, the India aquaculture feed market was valued at USD 3.25 billion in 2025 (Mordor Intelligence, 2026) and is projected to reach USD 3.47 billion by 2026.

Aquaculture production volume stands at 15.53 million tons in 2025 and is projected to reach 30.88 million tons by 2034 at a CAGR of 7.27 percent (2026 to 2034). Globally, the aquaculture healthcare market was valued at USD 1.35 billion in 2025, grew to USD 1.47 billion in 2026, and is projected to hit USD 3.04 billion by 2035.</p><p>The Indian veterinary pharmaceutical sector reached USD 1,242.5 million in 2025, while the veterinary active pharmaceutical ingredients (API) market recorded revenue of USD 547.7 million in 2024 and is projected to reach USD 1,133.3 million by 2033. Regionally, Andhra Pradesh dominates the national market with a 78.0 percent share of total production under its Fisheries Policy 2020 to 2025 (IMARC Group, 2025).

West Bengal secures the second-highest production volume, notably leading in Black Tiger shrimp production at 19,190 MT in 2020 to 2021 (MPEDA, 2021). Gujarat and Tamil Nadu also hold significant production shares. Asia-Pacific dominates the global aquaculture feed and pharmaceutical market with approximately 73 percent market share, driven by health management solutions, vaccines, and immunostimulants.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>Aquaculture medicine manufacturing in India is adopting advanced technological processes to ensure quality, safety, and efficacy. Real-time microbial activity sensors, such as AquaSignum deployed in 2025, are being implemented to control active pathogen environments during drug administration and manufacturing runs. Genome editing and biomass optimization technologies, including high-speed DNA editing platforms such as Regional Fish (2025), are being integrated to enhance therapeutic outcomes and develop targeted health interventions for aquatic species.</p><p>At the facility level, capital requirements vary significantly by scale.

A small-scale veterinary or medicine plant targeting the domestic market requires INR 5 crores to INR 15 crores (2026 data), while a mid-scale plant capable of multi-formulation production for export demands INR 50 crores to INR 80 crores (2026 data). A large-scale or advanced facility producing injectables or APIs requires INR 100 crores to INR 250 plus crores (2026 data). Land and site development typically accounts for 8 percent to 15 percent of the total budget.

Artificial intelligence and IoT integration are emerging as key automation trends in the broader aquaculture sector, and recirculating aquaculture systems (RAS) technology can deliver up to 90 percent to 99 percent water savings compared to traditional open ponds, creating new requirements for disease management in high-density, controlled-environment settings.</p>

For a aquaculture medicine project at ₹4.7 crore - ₹52 crore CapEx with a 2.2 - 4.9-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

<p>The sector faces significant operational and regulatory risks. Annual global economic loss due to aquatic diseases is estimated at USD 6 billion (World Bank, 2014), underscoring the endemic disease burden that directly threatens farm profitability and investor returns. Higher stocking densities in recirculating aquaculture systems and intensive coastal ponds amplify pathogen transmission rates, creating volatile demand cycles tied to disease outbreak patterns.

The dual market structure, where a fragmented unorganized segment relies on local concoctions, generic unregistered chemicals, and traditional remedies, creates quality inconsistency and regulatory enforcement challenges that can undermine branded product trust.</p><p>Regulatory risk is acute: the CAA Rules, 2024 enforce strict prohibitions on banned pharmacologically active substances, and CDSCO oversight under the Drugs and Cosmetics Act, 1940 requires rigorous compliance for new product registrations. The GST rate of 5 percent effective September 22, 2025, while modest, adds to input cost structures already pressured by shrimp feed costs ranging between INR 55 and INR 75 per kg, which account for 50 percent to 60 percent of total production costs. Soybean meal commands a 28 percent market share among input raw materials.

Environmental and climate risks include changing water temperatures and quality parameters that can destabilize farm health profiles and shift therapeutic demand unpredictably. Additionally, the aquaculture stewardship council feed standard V1.2 introduces energy efficiency and sustainability norms that may increase compliance costs for medicine and feed manufacturers. The sector also remains vulnerable to seafood trade disruptions, as export market access depends heavily on meeting importing country residue limits and food safety certification requirements.</p>